Piper Sandler Increases Becton, Dickinson and Company (NYSE:BDX) Price Target to $200.00

Key Points

• Piper Sandler has raised its price target for Becton, Dickinson and Company (NYSE:BDX) from $185.00 to $200.00, indicating a potential upside of 6.68% from the current price.
• Several other firms have adjusted their ratings on BDX, with Goldman Sachs downgrading it from "buy" to "neutral" and setting a price target of $192.00.
• Becton, Dickinson reported quarterly earnings of $3.68 per share, exceeding analysts' expectations, with a revenue of $5.51 billion, reflecting a 10.4% year-over-year increase.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) had its price objective increased by Piper Sandler from $185.00 to $200.00 in a report issued on Friday,Benzinga reports. The firm currently has a "neutral" rating on the medical instruments supplier's stock. Piper Sandler's price target would indicate a potential upside of 6.68% from the company's current price.

BDX has been the subject of a number of other research reports. The Goldman Sachs Group downgraded Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a report on Friday, May 2nd. Wells Fargo & Company downgraded Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their price objective for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Barclays dropped their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $214.75.

Becton, Dickinson and Company Stock Up 8.7%

Shares of Becton, Dickinson and Company stock opened at $187.49 on Friday. The company has a fifty day moving average price of $175.39 and a 200 day moving average price of $199.30. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock has a market cap of $53.73 billion, a price-to-earnings ratio of 35.78, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The firm had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. Becton, Dickinson and Company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.50 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Shan sold 1,166 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.36% of the company's stock.

Institutional Investors Weigh In On Becton, Dickinson and Company

Large investors have recently bought and sold shares of the business. First Eagle Investment Management LLC grew its stake in Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier's stock valued at $1,513,421,000 after acquiring an additional 3,268,478 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 36.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after purchasing an additional 3,219,317 shares in the last quarter. GQG Partners LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $689,833,000. Kovitz Investment Group Partners LLC increased its stake in Becton, Dickinson and Company by 392.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock worth $775,139,000 after purchasing an additional 2,722,829 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the period. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.